ClinicalTrials.gg
RecruitingNCT06516822SINUSUpdated Nov 8, 2024

CPVI With Modified Linear Ablation Versus CPVI in Patients With Long-standing Persistent Atrial Fibrillation (SINUS)

An interventional study of CPVI-MLA and CPVI only in Long-standing Persistent Atrial Fibrillation and Ablation, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 10 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
320
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Atrial Fibrillation by The First Affiliated Hospital with Nanjing Medical University — 3 open to participants now, 3 under way, none of them phase 3. Atrial Fibrillation · The First Affiliated Hospital with Nanjing Medical University.

Planned enrollment
4th of 14
320 · median 205
Started
2024
the only one that year
No phase
12 of 16
3 open now
Registered
15th of 16
by date

Among the 16 studies in Atrial Fibrillation by The First Affiliated Hospital with Nanjing Medical University, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is one of 12 with no phase, and was the 15th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 16 studies in Atrial Fibrillation by The First Affiliated Hospital with Nanjing Medical University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Atrial Fibrillation by The First Affiliated Hospital with Nanjing Medical University, or all of them as a file.
02

Study summary

Catheter ablation has become as the first-line treatment for patients with symptomatic atrial fibrillation (AF). As the cornerstone of catheter ablation for AF, the safety and efficacy of circumferential pulmonary vein isolation (CPVI) have been confirmed. However, for persistent AF, especially for long-standing persistent AF (LSPAF), the recurrence rate is still high. Whether the ethanol infusion (EI) into the vein of Marshall (EI-VOM) and linear ablation could improve the success rate remains controversial.

The SINUS study is a prospective, multicenter, randomized trial, which is designed to compare the efficacy and safety between CPVI with modified linear ablation (CPVI-MLA) and CPVI only for the treatment of LSPAF.

Read the detailed description

The SINUS study will include 320 patients with LSPAF undergoing catheter ablation for the first time. All patients will be randomized to either the CPVI-MLA group or CPVI only group in a 1:1 ratio. The CPVI-MLA strategy is a fixed ablation approach consisting of EI-VOM, CPVI, left atrial posterior wall isolation (PWI), linear ablation of mitral isthmus (MI), left atrial intima adjoining CS (LAI-CS) and cavo-tricuspid isthmus (CTI), and superior vena cava isolation (SVCI). The follow-up is for a minimum of 12 months with rhythm monitoring. The primary endpoint is freedom from any documented atrial arrhythmia including atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) > 30 seconds after the initial 3 months blanking period without the use of antiarrhythmic drugs (AADs), at 12 months after the index ablation procedure.

03

Conditions studied

  • Long-standing Persistent Atrial Fibrillation
  • Ablation

Browse trials for

Keywords

  • long-standing persistent atrial fibrillation
  • circumferential pulmonary vein isolation
  • modified linear ablation
  • arrhythmia-free survival
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Patients with symptomatic LSPAF to at least one antiarrhythmic drug; LSPAF will be defined as a sustained AF episode lasting ≥ 1 year;
  1. AF duration 1-3 years;
  2. Age 18 - 75 years;
  3. Left atrial diameter (LAD) 43-55 mm on long axis parasternal view;
  4. AF recorded within 3 years of enrollment;
  5. Patient willing and able to comply with protocol and sign

Exclusion criteria

Exclusion Criteria:

  1. Paroxysmal atrial fibrillation;
  2. Persistent AF lasting \< 1 year or >3 years;
  3. Left atrial thrombosis;
  4. Patients with a history of catheter ablation for AF;
  5. Patients with severe structural heart disease (severe valvular heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy, etc.);
  6. LAD > 55mm on long axis parasternal view;
  7. (LVEF) \< 40%;
  8. Patients with to low molecular weight heparin, warfarin or novel oral anticoagulants;
  9. One-stop procedure for AF ablation and left atrial appendage occlusion;
  10. Alcohol allergy or contrast agent allergy;
  11. Patients taking cephalosporin antibiotics within 72 hours prior to ablation;
  12. Pulmonary artery systolic pressure > 50mmHg;
  13. Patients with unstable angina pectoris;
  14. Patients who had undergone percutaneous coronary intervention (PCI) within 3 months;
  15. Patients who had undergone surgery within 6 months;
  16. Patients ready to receive heart transplantation;
  17. Patients with a history of thromboembolism within 6 months;
  18. Patients with diagnosed atrial myxoma;
  19. Patients with severe respiratory diseases;
  20. Patients with infectious diseases in active phase;
  21. Patients with poorly controlled systemic immune diseases;
  22. Patients with uncured malignant hematological diseases;
  23. Patients with uncured malignant solid tumors;
  24. Patients with untreated hypothyroidism or hyperthyroidism;
  25. Patients with severe liver dysfunction (elevation of transaminases [ or AST] >3 times the );
  26. Patients with end-stage renal failure requiring dialysis;
  27. Patients with other serious arrhythmias, such as ventricular tachycardia with hemodynamic instability;
  28. Pregnant and lactating women;
  29. Patients with psychiatric ailments;
  30. \< 18.5 or ≥ 30kg/m2;
  31. \< 2 years;
  32. Patients unwilling or unable to give ;
  33. Patients unwilling or unable to cooperate to complete follow-up.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
320 participants (estimated)

Study arms

  • Experimental
    CPVI-MLA

    Patients randomized to the CPVI-MLA group first undergo ethanol infusion in the vein of Marshall (EI-VOM) followed by CPVI, left atrial posterior wall isolation (PWI), linear ablation of mitral isthmus (MI), left atrial intima adjoining CS (LAI-CS) and cavo-tricuspid isthmus (CTI), and superior vena cava isolation (SVCI).

    Procedure: CPVI-MLA

  • Active comparator
    CPVI only

    Patients randomized to the CPVI group undergo right PV ablation, followed by the left PV ablation. Radiofrequency ablation should be applied at least 1-2 cm outside of the PV ostia in a wide-area circumferential pattern. Complete CPVI is achieved when all PV potentials within each antrum recorded by the high-density mapping catheter are abolished.

    Procedure: CPVI only

Interventions

  • ProcedureCPVI-MLA

    The details include: (1) EI-VOM procedure: An 8.5-French-long sheath is inserted into to the CS via the femoral vein. A JR4 catheter is inserted into the CS to identify the ostium of the VOM. Subsequently, a guide wire supported by an OTW balloon catheter is advanced into the VOM. The balloon is inflated at 6-8 atm pressure in the VOM. Ethanol is infused into VOM from distal to proximal with 3ml each time within 1-2min. After the distal EI-VOM, the balloon is deflated and adjusted to the middle part of VOM. The EI-VOM procedure in the proximal and middle part of VOM should be the same as that in the distal. After three times of EI-VOM, the contrast is injected into VOM to make it permeable and dispersed to observe the effect of alcohol ablation. (2) After EI-VOM, radiofrequency ablation is performed to achieve bilateral PVI, PWI, bidirectional block of MI and CTI, disappearance of LAI-CS potential and SVCI. (3) Any organized AT observed during the procedure is targeted as well.

  • ProcedureCPVI only

    After reconstructing the left atrial geometry, CPVI is performed. Radiofrequency ablation should be applied at least 1-2 cm outside of the PV ostia for PVI to achieve a wide PVI ring. The mapping catheter PentaRay will be used to confirm the complete isolation of the PV antrum when all PV potentials within each antrum are abolished. If the AF persists after CPVI, direct current cardioversion is then be conducted to restore sinus rhythm. If spontaneous AFL/AT occurs during ablation, ablation is performed targeting the focal or critical isthmus under the guidance of high-density activation mapping. The endpoint of CPVI is to achieve complete entrance and exit block of all PV antra as recorded by PentaRay during sinus rhythm or CS pacing.

06

What researchers measure

Primary outcomes

  1. Freedom from any documented atrial arrhythmia off AADs

    Freedom from any documented atrial arrhythmia including atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) \> 30 seconds assessed by ECG and Holter after the initial 3 months blanking period without the use of antiarrhythmic drugs (AADs), after the index ablation procedure

    Time frame: 12 months

Secondary outcomes

  1. Freedom from any documented atrial arrhythmia on/off AADs

    Freedom from any documented atrial arrhythmia \> 30 seconds assessed by ECG and Holter after the initial 3 month blanking period, after the index ablation procedure on/off AADs.

    Time frame: 12 months

  2. Freedom from any documented AF on/off AADs

    Freedom from any documented AF episodes \> 30 seconds assessed by ECG and Holter after the initial 3 month blanking period, after the index ablation procedure on/off AADs.

    Time frame: 12 months

  3. Freedom from any documented AFL/AT on/off AADs

    Freedom from any documented AFL/AT episodes \> 30 seconds assessed by ECG and Holter after the initial 3 month blanking period, after the index ablation procedure on/off AADs.

    Time frame: 12 months

  4. AF burden

    AF burden (% time) on continuous monitoring during 12 months after the 3-months blanking period.

    Time frame: 12 months

  5. Freedom from any documented AFL/AT on/off AADs in patients with successful EI-VOM

    Freedom from any documented AFL/AT episodes \> 30 seconds assessed by ECG and Holter after the initial 3 month blanking period, after the index ablation procedure on/off AADs in patients with successful EI-VOM.

    Time frame: 12 months

  6. AF burden in patients with successful EI-VOM

    AF burden (% time) on continuous monitoring during 12 months after the 3-months blanking period in patients with successful EI-VOM

    Time frame: 12 months

  7. Freedom from AF/AFL/AT after multiple procedures

    Freedom from any documented atrial arrhythmia \> 30 seconds assessed by ECG and Holter after the initial 3 month blanking period, after more than one ablation procedure on/off AADs.

    Time frame: 12 months

  8. Freedom from AF after multiple procedures

    Freedom from any documented AF \> 30 seconds assessed by ECG and Holter after the initial 3 month blanking period, after more than one ablation procedure on/off AADs.

    Time frame: 12 months

  9. Freedom from AFL/AT after multiple procedures

    Freedom from any documented AFL/AT \> 30 seconds assessed by ECG and Holter after the initial 3 month blanking period, after more than one ablation procedure on/off AADs.

    Time frame: 12 months

  10. AF burden after multiple procedures

    AF burden (% time) on continuous monitoring during 12 months (after the 3-months blanking period) after multiple procedures

    Time frame: 12 months

  11. Hospitalization for cardiovascular disease

    Hospitalization for cardiovascular disease (e.g., atrial arrhythmia, heart failure and coronary heart disease)

    Time frame: 12 months

  12. AFEQT score change between baseline and 12-month

    Quality of life assessed by AF effect on quality-of-life (AFEQT) questionnaire

    Time frame: 12 months

  13. EQ-5D-5L score change between baseline and 12-month

    Quality of life assessed by EuroQol 5-dimension (EQ-5D-5L) scale

    Time frame: 12 months

  14. Incidence of procedural complications

    Cardiac tamponade or perforation, phrenic nerve injury, acute coronary occlusion, death, stroke / thromboembolism related to AF ablation, pulmonary vein stenosis, left atrial oesophageal fistula, and vascular complications requiring intervention (e.g., pseudoaneurysm, arteriovenous fistula).

    Time frame: Within 3 months after the procedure

07

Study locations

2 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — The data used and analyzed to support the study are available from the principal investigator on reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2027, 41 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 41 months is close to that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Jul 24, 2024
StartActual
Jul 31, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06516822
Responsible party
Zhang Fengxiang (Deputy Director of Cardiology, Principal Investigator, Clinical Professor, The First Affiliated Hospital with Nanjing Medical University) — Principal investigator
First posted
Jul 24, 2024
Start date
Jul 31, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 8, 2024

Study contacts

Yan Dong, MD
Contact
dy_medical@163.com
+86 18651908170
Qiushi Chen, MD
Contact
chenqs918@163.com
Fengxiang Zhang, MD
principal investigator · The First Affiliated Hospital with Nanjing Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion